Evolving Therapeutic Landscape of ROS1-Positive Non-Small Cell Lung Cancer: An Updated Review

ROS1 gene rearrangements define a distinct molecular subtype of non-small cell lung cancer (NSCLC), occurring in approximately 2% of cases and frequently associated with younger age, non-smoker status, and a high incidence of brain metastases. The discovery of ROS1 as an oncogenic driver has led to...

Full description

Saved in:

Bibliographic Details
Published in:	Current oncology (Toronto) Vol. 32; no. 11; p. 626
Main Authors:	Bischoff, Hervé, Gendarme, Sébastien, Somme, Laura, Chouaid, Christos, Schott, Roland
Format:	Journal Article
Language:	English
Published:	Switzerland MDPI AG 06.11.2025
Subjects:	Antimitotic agents Antineoplastic agents brain metastases Cancer Carcinoma, Non-Small-Cell Lung - drug therapy Carcinoma, Non-Small-Cell Lung - genetics Carcinoma, Non-Small-Cell Lung - pathology Development and progression Drug Resistance, Neoplasm Genetic aspects Genetic research Health aspects Humans Lung cancer, Non-small cell Lung cancer, Small cell Lung Neoplasms - drug therapy Lung Neoplasms - genetics Lung Neoplasms - pathology Medical research Medicine, Experimental Metastasis non-small cell lung cancer Protein Kinase Inhibitors - pharmacology Protein Kinase Inhibitors - therapeutic use Protein-Tyrosine Kinases - antagonists & inhibitors Protein-Tyrosine Kinases - genetics Protein-Tyrosine Kinases - metabolism Proto-Oncogene Proteins - antagonists & inhibitors Proto-Oncogene Proteins - genetics Proto-Oncogene Proteins - metabolism resistance mutations ROS1 targeted therapy Tyrosine tyrosine kinase inhibitor France Spain non-small cell lung cancer targeted therapy repotrectinib taletrectinib brain metastases tyrosine kinase inhibitor ROS1 resistance mutations zidesamtinib
ISSN:	1718-7729, 1198-0052, 1718-7729
Online Access:	Get full text
Tags:	Add Tag No Tags, Be the first to tag this record!

Be the first to leave a comment!